Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients with Cardiovascular Disease: A Prespecified Analysis from the FOURIER Trial

JAMA Cardiology

Volumn 4, Issue 7, 2019, Pages 613-619

  Murphy, Sabina A ^a   Pedersen, Terje R ^b   Gaciong, Zbigniew A ^c   Ceska, Richard ^d   Ezhov, Marat V ^e   Connolly, Derek L ^f   Jukema, J Wouter ^g   Toth, Kalman ^h   Tikkanen, Matti J ⁱ   Im, Kyungah ^a   Wiviott, Stephen D ^a   Kurtz, Christopher E ^j   Honarpour, Narimon ^j   Giugliano, Robert P ^a   Keech, Anthony C ^k   Sever, Peter S ^l   Sabatine, Marc S ^a,m  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d CHARLES UNIVERSITY   (Czech Republic)

^e INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF PÉCS   (Hungary)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j AMGEN INC   (United States)

^k UNIVERSITY OF SYDNEY   (Australia)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m JAMA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; LOW DENSITY LIPOPROTEIN; PLACEBO; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VERY ELDERLY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPROTEIN CONVERTASE 9; STROKE; TREATMENT OUTCOME;

EID: 85066899039     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2019.0886     Document Type: Article

References (15)

1. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009; 54 (25): 2358-2362. doi: 10.1016/j.jacc.2009.10.005 20082923
2. Tikkanen MJ, Szarek M, Fayyad R,; IDEAL Investigators. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009; 54 (25): 2353-2357. doi: 10.1016/j.jacc.2009.08.035 20082922
3. Murphy SA, Cannon CP, Blazing MA, Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016; 67 (4): 353-361. doi: 10.1016/j.jacc.2015.10.077 26821621
4. Sabatine MS, Giugliano RP, Keech AC,; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376 (18): 1713-1722. doi: 10.1056/NEJMoa1615664 28304224
5. Sabatine MS, Giugliano RP, Keech A, Rationale and design of the further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk trial. Am Heart J. 2016; 173: 94-101. doi: 10.1016/j.ahj.2015.11.015 26920601
6. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989; 84: 1065-1073. doi: 10.1080/01621459.1989.10478873
7. Baigent C, Keech A, Kearney PM,; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493): 1267-1278. doi: 10.1016/S0140-6736(05)67394-1 16214597
8. Baigent C, Blackwell L, Emberson J,; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670-1681. doi: 10.1016/S0140-6736(10)61350-5 21067804
9. Cannon CP, Braunwald E, McCabe CH,; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350 (15): 1495-1504. doi: 10.1056/NEJMoa040583 15007110
10. de Lemos JA, Blazing MA, Wiviott SD,; Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292 (11): 1307-1316. doi: 10.1001/jama.292.11.1307 15337732
11. LaRosa JC, Grundy SM, Waters DD,; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352 (14): 1425-1435. doi: 10.1056/NEJMoa050461 15755765
12. Pedersen TR, Faergeman O, Kastelein JJ,; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294 (19): 2437-2445. doi: 10.1001/jama.294.19.2437 16287954
13. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48 (3): 438-445. doi: 10.1016/j.jacc.2006.04.070 16875966
14. LaRosa JC, Deedwania PC, Shepherd J,; TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010; 105 (3): 283-287. doi: 10.1016/j.amjcard.2009.09.025 20102935
15. Landmesser U, Chapman MJ, Farnier M,; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017; 38 (29): 2245-2255. 27789571